Corticosteroids for COVID-19-Associated ARDS

Q4 Medicine Clinical Pulmonary Medicine Pub Date : 2020-11-01 DOI:10.1097/cpm.0000000000000381

M. Marmor, A. Jonas

引用次数: 4

Abstract

Systemic corticosteroids have emerged as a possible therapy to mitigate lung injury in severe COVID-19 infection Here, we provide historical context for corticosteroid administration in acute respiratory failure due to viral infection and review existing data for the use of systemic corticosteroids for SARS-CoV-2 infection The results of these limited data consistently suggest a mortality benefit for patients with COVID-19-associated acute respiratory distress syndrome with no existing evidence to suggest harm © 2020 Lippincott Williams and Wilkins All rights reserved

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

皮质类固醇治疗COVID-19相关ARDS

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical Pulmonary Medicine Medicine-Critical Care and Intensive Care Medicine

自引率

0.00%

发文量

期刊介绍： Clinical Pulmonary Medicine provides a forum for the discussion of important new knowledge in the field of pulmonary medicine that is of interest and relevance to the practitioner. This goal is achieved through mini-reviews on focused sub-specialty topics in areas covered within the journal. These areas include: Obstructive Airways Disease; Respiratory Infections; Interstitial, Inflammatory, and Occupational Diseases; Clinical Practice Management; Critical Care/Respiratory Care; Colleagues in Respiratory Medicine; and Topics in Respiratory Medicine.